{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:14:23Z","timestamp":1790028863559,"version":"4.0.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030841","name":"Exact Sciences Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030841","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008067","name":"Exact Sciences Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006344","name":"Sandro Pitigliani Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006344","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejca.2024.115108","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T04:58:01Z","timestamp":1730437081000},"page":"115108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Prospective study on Oncotype DX\u00ae assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial"],"prefix":"10.1016","volume":"213","author":[{"given":"Luca","family":"Livraghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Martella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Ghilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catia","family":"Angiolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Magnanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Bengala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Risi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Molinara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Pazzagli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Malorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Gabellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Martignetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Giannessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Sanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Barellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Biagioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Roncella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Biganzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.ejca.2024.115108_bib1","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1200\/JCO.19.00945","article-title":"Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO clinical practice guideline update-integration of results from TAILORx","volume":"37","author":"Andre","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2024.115108_bib2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.18.01160","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update","volume":"37","author":"Burstein","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.115108_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1016\/j.ejca.2024.115108_bib4","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","volume":"351","author":"Paik","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2024.115108_bib5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10549-010-1331-z","article-title":"Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20","volume":"127","author":"Tang","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"10.1016\/j.ejca.2024.115108_bib6","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2009.24.4798","article-title":"Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study","volume":"28","author":"Dowsett","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2024.115108_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(09)70314-6","article-title":"Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial","volume":"11","author":"Albain","year":"2010","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.ejca.2024.115108_bib8","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective validation of a 21-gene expression assay in breast cancer","volume":"373","author":"Sparano","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2024.115108_bib9","unstructured":"Gazzetta Ufficiale della Repubblica Italiana, DECRETO 18 maggio 2021, Modalita' di riparto e requisiti di utilizzo del fondo per i test genomici ormonoresponsivo per il carcinoma mammario in stadio precoce. Serie Generale n.161 del 07\u201307-2021."},{"issue":"2","key":"10.1016\/j.ejca.2024.115108_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ejca.2024.115108_bib11","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.ejca.2024.115108_bib12","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","article-title":"Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer","volume":"380","author":"Sparano","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejca.2024.115108_bib13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.20.03007","article-title":"Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer","volume":"39","author":"Sparano","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.115108_bib14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.breast.2018.12.015","article-title":"Results of PONDx, a prospective multicenter study of the Oncotype DX((R)) breast cancer assay: real-life utilization and decision impact in French clinical practice.","volume":"44","author":"Curtit","year":"2019","journal-title":"Breast"},{"issue":"1","key":"10.1016\/j.ejca.2024.115108_bib15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41523-021-00246-4","article-title":"PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy","volume":"7","author":"Cognetti","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ejca.2024.115108_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2020.04.003","article-title":"Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: the BONDX study","volume":"52","author":"Zambelli","year":"2020","journal-title":"Breast"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924017155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924017155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T08:33:54Z","timestamp":1733992434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924017155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":16,"alternative-id":["S0959804924017155"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115108","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective study on Oncotype DX\u00ae assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.115108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115108"}}